Regenerative medicine to reverse the root causes of degenerative diseases
Celvion Labs develops RNA-enhanced exosomes designed to reduce inflammation, restore cellular balance, and address degenerative diseases at their biological roots.
Degenerative diseases
challenge our society models
As people live longer, staying healthy throughout those extra years has become a growing challenge. While lifespans have increased, healthspan the time spent in good health has not kept up, largely due to the rise of inflammatory and degenerative diseases.
Modern lifestyles and longer lifespans have worsened age-related conditions, putting more stain on healthcare systems and reducing quality of life.
Our Technology Platform &
Therapeutic Focus
Personalized home care designed to support seniors in living safely, comfortably, and with the dignity they deserve.
Cell Sourcing
therapeutic exosomes are secreted from our proprietary hTert-immortalized Wharton’s jelly mesenchymal stem cells. This cell line combines the regenerative potency of primary MSCs with the scalability and consistency required for clinical-grade exosome manufacturing. It forms the foundation of a reliable, high-yield, and reproducible exosomes production platform built for therapeutic development.
Manufacturing
Engineering
Proprietary perfused bioreactors enable industrial-scale production at costs 40x cheaper than competitors. This overcomes the common scaling challenges in regenerative medicine.
Our patented microfluidic-based loading technology is based on a temporary mechanical porosity of the exosomes for payload absorption (mechanoporation). This process enables the loading of cargo, such as RNA, into exosomes without altering their natural therapeutic properties, boosting efficacy while preserving their integrity. Competing methods often compromise exosome quality or increase rejection risk.
From Discovery to Clinical Translation
Our therapeutic pipeline is built on a platform that enhances the natural regenerative power of exosomes. By engineering RNA cargo and optimizing delivery, we aim to address the underlying drivers of inflammation and degenerative disease. Each stage of our process brings us closer to developing therapies that restore cellular health and improve long-term outcomes.
Our Mission:
Delivering Treatments for Degenerative Diseases Using the Body’s Natural Healing Messengers, Making Them Affordable and Accessible to All
We focus on extending healthspan, the years of life lived in good health, by augmenting the power of exosomes, tiny stem cell-derived vesicles that naturally carry anti-inflammatory and regenerative signals. These exosomes represent the next generation of cell-free therapies, and we uniquely enhance their therapeutic potential with additional payloads such as RNA.
The result? Potent, scalable, and affordable technology platform helps restore balance and regenerative capacity across multiple disease pathways.
Advancing the Future of RNA-Enhanced Exosomes Therapeutics
Celvion Labs is focused on unlocking the power of RNA-enhanced exosomes. Founded in 2025 by experts in cell therapy, biologics, and advanced manufacturing, the company is building a scalable platform that makes next-generation treatments more accessible, more consistent, and more affordable. Celvion Labs revolutionizing large-scale production of RNA-enhanced exosomes by combining cutting-edge manufacturing technology with advanced exosome enrichment systems.
Using its proprietary technology platform, Celvion Labs is developing an exclusive therapeutic portfolio to address osteoarthritis and dermatological conditions.
Through strategic partnerships, Celvion Labs is also expanding its focus to tackle anti aging, cell regeneration, chronic inflammatory, gut, kidney, and neuro-related diseases.
The mission is simple: bring meaningful exosomes innovation to consumers worldwide.
